Phase 3
N=50
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication
Uterine Leiomyoma · Uterine Fibroids
Bottom Line
View on ClinicalTrials.gov: NCT00365989 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Number of Adverse Events — 77; 75 Adverse Events
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- ExAblate Enhanced Sonication (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- InSightec
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Adverse Events |
77; 75 | — |
Summary
This is a phase 3 study to determine the safety of the new features to the FDA approved ExAblate device using a new method to ablate fibroids deemed Enhanced Sonication.
Eligibility Criteria
Inclusion Criteria
- Women age 18 or older, who present with symptomatic fibroids
- Women who have given written informed consent
- Women who are able and willing to attend all study visits.
- Patient is pre or peri-menopausal (within 12 months of last menstrual period).
- Able to communicate sensations during the ExAblate procedure.
- Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
- Fibroids(s) clearly visible on non-contrast MRI.
Exclusion Criteria
- Women who are pregnant, as confirmed by serum test at time of screening, or urine pregnancy test on the day of treatment
- Patient who desire to become pregnant in the future.
- Patients who are breast-feeding.
- Patients with an active pelvic inflammatory disease (PID)
- Active local or systemic infection
- Metallic implants that are incompatible with MRI
- Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)
- Severe claustrophobia that would prevent completion of procedure in the MR unit.
- Extensive abdominal scarring in the beam pass or dermoid cyst of the ovary anywhere in the treatment path.
- Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.
- Pedunculated fibroids.
- Intrauterine device (IUD) anywhere in the treatment path
- Undiagnosed vaginal bleeding.
Data sourced from ClinicalTrials.gov (NCT00365989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.